foxo4-dri peptide senolytic 2023 inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis FOXO4-DRI - Averix Labs

In some embodiments, the otic formulation or composition comprises about 0.05% by weight of the therapeutic agent, or pharmaceutically acceptable prodrug or salt thereof

At 1 h after administration, [ 3 H]proline accounted for 86.65% of the plasma radioactive components

The quantitative 1 H-NMR spectrum was acquired using a Bruker standard 1D lc1pngppsf2 pulse sequence with 32 scans

Suitable for studies involving peptide characterization and method development in model systems.Not for human use

The Drugs@FDA database contains no entry for BPC-157 in any indication, and ClinicalTrials.gov shows no ongoing human studies registered in the United States

In February 2026, the U.S